BridgeBio readies potential first LGMD2I/R9 therapy as FDA decision on BBP-418 nears
What's happening: BridgeBio says it is weeks away from a potential US approval for its oral drug BBP-418, with the FDA decision (PDUFA date) set for 27 November 2026 under Priority Review and no advisory committee planned. The drug treats limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a rare inherited disease in which a faulty FKRP protein (which normally helps build and repair muscle) leaves patients with progressive weakening that starts in the hips and shoulders and can eventually reach the heart and breathing muscles. If approved, BBP-418 would be the first approved therapy for any form of limb-girdle muscular dystrophy.
Why it matters: BridgeBio's 29 October 2026 third-quarter update says launch preparation is well advanced: roughly 70% of patients are concentrated at MDA Care Centers, the field team has reached over 70% of those centres, with a target of 90% by the decision date, and commercial teams for the programme are hired and ready. In Europe, after talks with national health authorities, the company plans to submit a marketing authorisation application to the EMA in the first half of 2028.
The evidence behind it: The filing rests on the Phase 3 FORTIFY trial, which met all primary and secondary endpoints at its pre-specified 12-month interim analysis. New exploratory cardiac data presented at the World Muscle Society Congress 2026 show that after 12 months, 100% of BBP-418-treated patients who started with elevated troponin (a blood marker of heart-muscle injury) returned to normal levels, versus 40% on placebo (p=0.0248); and 54% of treated patients had stable or improved heart-pumping function (LVEF), versus 25% on placebo (p=0.0262) — a meaningful signal, since heart involvement is a major cause of illness and death in this disease. BBP-418 works by supplying a sugar-like molecule that the defective FKRP protein can no longer attach properly, restoring the protein coating that keeps muscle cells intact.
Read more: BridgeBio, 29 October 2026 · BioSpace, 27 May 2026
